270 related articles for article (PubMed ID: 19022661)
41. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
42. Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells.
Kwok S; Rittling SR; Partridge NC; Benson CS; Thiyagaraj M; Srinivasan N; Selvamurugan N
J Cell Biochem; 2009 Oct; 108(2):408-14. PubMed ID: 19582787
[TBL] [Abstract][Full Text] [Related]
43. The metastatic process: basic research and clinical implications.
Chambers AF
Oncol Res; 1999; 11(4):161-8. PubMed ID: 10566614
[TBL] [Abstract][Full Text] [Related]
44. Researchers exploring implications of minimal residual cancer.
McBride G
J Natl Cancer Inst; 2005 Nov; 97(22):1642-3. PubMed ID: 16288116
[No Abstract] [Full Text] [Related]
45. Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma.
Vincent-Salomon A; Caly M; De Rycke Y; Fréneaux P; Klijanienko J; Laé M; Viard F; Nos C; Bidard FC; Alran S; Salmon R; Kirova Y; Pierga JY; Sigal-Zafrani B; Sastre-Garau X
Eur J Cancer; 2009 Jul; 45(11):1979-86. PubMed ID: 19375305
[TBL] [Abstract][Full Text] [Related]
46. Circulating and disseminated tumor cells in the management of breast cancer.
Ross JS; Slodkowska EA
Am J Clin Pathol; 2009 Aug; 132(2):237-45. PubMed ID: 19605818
[TBL] [Abstract][Full Text] [Related]
47. Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis.
Bluemke K; Bilkenroth U; Meye A; Fuessel S; Lautenschlaeger C; Goebel S; Melchior A; Heynemann H; Fornara P; Taubert H
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2190-4. PubMed ID: 19661076
[TBL] [Abstract][Full Text] [Related]
48. [Disseminated intravascular coagulation syndrome as a manifestation of breast adenocarcinoma metastasis].
Ludwig J; Kentos A; Crenier L; Dargent JL; Capel P; Feremans W
Rev Med Brux; 1997 Dec; 18(6):385-8. PubMed ID: 9481159
[TBL] [Abstract][Full Text] [Related]
49. Tumor dormancy and metastasis.
Hedley BD; Chambers AF
Adv Cancer Res; 2009; 102():67-101. PubMed ID: 19595307
[TBL] [Abstract][Full Text] [Related]
50. Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.
Saha S; Ali S; Ghanem M; Soni M; Wiese D; Arora M; Singh T; Iddings D
Ann Surg Oncol; 2009 Feb; 16(2):276-80. PubMed ID: 19050967
[TBL] [Abstract][Full Text] [Related]
51. Metastatic tumors in bone marrow: histopathology and advances in the biology of the tumor cells and bone marrow environment.
Cotta CV; Konoplev S; Medeiros LJ; Bueso-Ramos CE
Ann Diagn Pathol; 2006 Jun; 10(3):169-92. PubMed ID: 16730315
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer.
Buergy D; Fuchs T; Kambakamba P; Mudduluru G; Maurer G; Post S; Tang Y; Nakada MT; Yan L; Allgayer H
Cancer; 2009 Oct; 115(20):4667-78. PubMed ID: 19569245
[TBL] [Abstract][Full Text] [Related]
53. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
[TBL] [Abstract][Full Text] [Related]
54. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer.
Mostert B; Sleijfer S; Foekens JA; Gratama JW
Cancer Treat Rev; 2009 Aug; 35(5):463-74. PubMed ID: 19410375
[TBL] [Abstract][Full Text] [Related]
55. Disseminated and circulating tumour cells and their role in breast cancer.
Čabiňaková M; Tesařová P
Folia Biol (Praha); 2012; 58(3):87-97. PubMed ID: 22849858
[TBL] [Abstract][Full Text] [Related]
56. Survival impact of integrative cancer care in advanced metastatic breast cancer.
Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
[TBL] [Abstract][Full Text] [Related]
57. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells.
Tachtsidis A; McInnes LM; Jacobsen N; Thompson EW; Saunders CM
Clin Exp Metastasis; 2016 Aug; 33(6):521-50. PubMed ID: 27189371
[TBL] [Abstract][Full Text] [Related]
58. Circulating tumor cells in metastatic breast cancer--toward individualized treatment?
Braun S; Marth C
N Engl J Med; 2004 Aug; 351(8):824-6. PubMed ID: 15317898
[No Abstract] [Full Text] [Related]
59. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Coleman RE
Eur J Cancer; 2009 Jul; 45(11):1909-15. PubMed ID: 19447606
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.
Liu S; Goldstein RH; Scepansky EM; Rosenblatt M
Cancer Res; 2009 Nov; 69(22):8742-51. PubMed ID: 19887617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
